* AnaptysBio Inc ANAB.OQ ANAB.O is expected to show a
rise in
quarterly revenue when it reports results on August 9
(estimated) for the period ending June 30 2024
* The San Diego California-based company is expected to
report a
602.3% increase in revenue to $24.301 million from $3.46 million
a year ago, according to the mean estimate from 10 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for AnaptysBio Inc is for a
loss
of 89 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for AnaptysBio
Inc is
$48.50, above its last closing price of $32.76.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -1.56 -1.57 -1.59 Missed -4.7
Dec. 31 2024 -1.62 -1.59 0.7
Jun. 30 2023 -1.80 -1.79 -1.41 Beat 21.4
Jan. 1 0001 -1.83 -1.50 11.6
Mar. -1.08 -1.58
31 2023
Dec. 31 2022 -0.96 -0.96 -1.18 Missed 2.8
Sep. 30 2022 -0.65 -0.72 -1.18 Missed -63.1
Jun. 30 2022 -0.89 -1.02 -1.15 Missed -12.6
This summary was machine generated August 3 at 02:05 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)